Make or break for Portugal in 2002?
This article was originally published in Clinica
"2002 is going to be a very strange year" - and a strained one too for the Portuguese medical technology industry, from what Humberto Costa, chairman of leading association Apormed, tells Clinica. Indeed, the problems it faces go beyond issues such as funding, which has already led to apparently insurmountable arrears. For Apormed, the problems afflicting the country's device industry are deeply embedded in systemic, cultural failings of the entire healthcare system, which is in need of reform. As the country prepares for a national election, in which healthcare is set to top the agenda, Mr Costa hints at what he would like to see in the leading parties' manifestos.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.